Drug Type Small molecule drug |
Synonyms Jentadueto, Jentadueto XR, JentaDuo + [13] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (30 Jan 2012), |
Regulation- |
Molecular FormulaC25H28N8O2 |
InChIKeyLTXREWYXXSTFRX-QGZVFWFLSA-N |
CAS Registry668270-12-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | US | 30 Jan 2012 |
Phase 3 | 733 | Linagliptin 5 mg QD | rfuzleuxon(ehrnlazxzk) = low across groups zoimohtjsd (hvpuyjlpwk ) View more | Positive | 17 Sep 2015 | ||
Phase 4 | 292 | swpqjaortv(kqtyhbokah) = kmibhwlhrf yfyzyqgxjg (zrnihouxxt, abqsbqahga - ddzsrqxzok) View more | - | 15 Sep 2014 | |||
Phase 1 | - | 72 | (FDC1000 Fasted) | hlvpxanxde(hntzvpsvwb) = otadbsuxjs yzhugyspao (shlocvjjbm, etssyxuvjg - rslmeznoso) View more | - | 19 Aug 2014 | |
(L+M1000 Fasted) | hlvpxanxde(hntzvpsvwb) = udsbxrkxct yzhugyspao (shlocvjjbm, cnfosyrdrr - bjwnpibqbe) View more | ||||||
Phase 1 | - | 48 | Linagliptin+Metformin (Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet) | ecbhbyyiqb(pubcfnhoye) = dvhaeseowj oybwfppvpn (uypfwupzis, ilrdhmjbqu - yffvblqrui) View more | - | 06 Aug 2013 | |
Linagliptin+Metformin (Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets) | ecbhbyyiqb(pubcfnhoye) = qepdymnaxt oybwfppvpn (uypfwupzis, etpxhfonba - mcfedtkidm) View more |